Asset Acquisition, Development And Regulatory Milestones

No definition available.

Name:	ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Initial Milestone

+ References

No definition available.

+ Details

Name:	ptct_AssetAcquisitionInitialMilestone
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Milestone, Amount

+ References

No definition available.

+ Details

Name:	ptct_AssetAcquisitionMilestoneAmount
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Net Sales Milestone

+ References

No definition available.

+ Details

Name:	ptct_AssetAcquisitionNetSalesMilestone
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contingent Liability, Cancellation and Forfeiture

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityCancellationAndForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage

+ References

No definition available.

+ Details

Name:	ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
Namespace Prefix:	ptct_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of development milestone obligation payments made during the period.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestoneObligationPaymentsMade
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development Milestone Payment Obligations, Cancellation and Forfeiture

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development Milestone Payment Obligations, net of cancellation and forfeiture

+ References

No definition available.

+ Details

Name:	ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment which the entity is obliged to pay upon regulatory approval

+ References

No definition available.

+ Details

Name:	ptct_MilestonePotentialAchievementsRegulatoryApproval
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ptct_PotentialRoyaltiesDueNetProductSales
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront Licensing Fee

+ References

No definition available.

+ Details

Name:	ptct_UpfrontLicensingFee
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=ptct_AkceaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ptct_CensaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptct_RightsExchangeAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and contingencies - Narrative (Details) - USD ($) $ in Millions			1 Months Ended			9 Months Ended	12 Months Ended
	Jun. 29, 2020	Apr. 29, 2020	Aug. 31, 2021	Dec. 31, 2019	May 31, 2019	Sep. 30, 2021	Dec. 31, 2019	May 29, 2020	Apr. 20, 2017	Jun. 30, 2016
Akcea
Other Commitments
Upfront licensing fee						$ 12.0
Milestone payments			$ 4.0
Akcea \| Maximum
Other Commitments
Milestone payments						4.0
Censa
Other Commitments
Asset acquisition, development and regulatory milestones								$ 109.0
Asset acquisition, initial milestone								30.0
Censa \| Maximum
Other Commitments
Asset acquisition, milestone, amount								217.5
Asset acquisition, net sales milestone								$ 160.0
Agilis Merger Agreement \| Marathon Pharmaceuticals, LLC
Other Commitments
Development milestone payments which the entity is obligated to pay									$ 50.0
Agilis Merger Agreement \| Akcea
Other Commitments
Milestone payments				$ 4.0	$ 6.0	4.0	$ 6.0
SMA License Agreement \| Maximum
Other Commitments
Potential royalty payments due on net product sales						52.5
Agilis
Other Commitments
Development milestone payments which the entity is obligated to pay						40.0
Development milestone obligation payments made						$ 2.4
Agilis \| Minimum
Other Commitments
Product sales (as a percent)		2.00%				2.00%
Agilis \| Maximum
Other Commitments
Development milestone payments which the entity is obligated to pay						$ 60.0
Priority review voucher amount						535.0
Net sales amount						$ 150.0
Product sales (as a percent)		6.00%				6.00%
Development milestone payment obligations, net of cancellation and forfeiture						$ 20.0
Agilis \| Rights Exchange Agreement
Other Commitments
Contingent liability cancellation and forfeiture of potential milestone payments						174.0
Development milestone payment obligations, cancellation and forfeiture						37.6
Contingent liability, cancellation and forfeiture	$ 211.6
Agilis \| Rights Exchange Agreement \| Maximum
Other Commitments
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture		$ 361.0
BioElectron \| Maximum
Other Commitments
Development milestone payments which the entity is obligated to pay						200.0
Net product revenue \| Wellcome Trust
Other Commitments
Development milestone payments which the entity is obligated to pay										$ 0.8
Net product revenue \| Wellcome Trust \| Maximum
Other Commitments
Development milestone payments which the entity is obligated to pay						$ 22.4